Therini Bio Raises Additional $39M Series A Financing to Advance Clinical Development of Neurodegenerative Disease Pipeline
SACRAMENTO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Therini Bio, Inc., a clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular dysfunction today announced that it raised $39 million in a Series A extension financing. The extension financing included new investors, Angelini Ventures and Apollo Health Ventures, in addition to existing investors SV Health Investors' Biotech Fund and Dementia Discovery Fund, MRL Ventures Fund, Sanofi Ventures, Eli Lilly and Company, Dolby Family Ventures and Foundation for a Better World. This financing increased Therini Bio's Series A total to $75M.
Therini Bio anticipates using the proceeds to fund Phase 1b trials evaluating its lead candidate, THN391, for the treatment of Alzheimer's Disease (AD) and Diabetic Macular Edema (DME), as well as support development of a fibrin/VEGF bispecific.
Therini Bio seeks to target the underlying causes of neurodegeneration. Factors such as aging, genetics and prevalent diseases, such as hypertension and diabetes, lead to vascular dysfunction and the accumulation of toxic fibrin deposits outside of blood vessels. These deposits induce chronic neuroinflammation, resulting in neuronal damage and severe neurogenerative diseases. Therini Bio has developed a novel approach aimed at treating these devastating diseases by specifically targeting the inflammatory epitope on fibrin to halt the destructive effects of neuroinflammation.
THN391, a potential first-in-class, high-affinity humanized monoclonal antibody designed to selectively block fibrin-mediated neuroinflammation without affecting coagulation pathways, demonstrated activity in preventing vascular and neuronal degeneration in preclinical studies of AD and retinal diseases. In a recent Phase 1a trial, THN391 was well-tolerated in healthy volunteers, showed no adverse hematological effects or impact on coagulation and fibrinolysis, lacked an anti-drug antibody response and had dose-proportional pharmacokinetics with a half-life supporting monthly dosing. Supported by the current data and financing, the experienced team at Therini Bio is preparing to begin dosing patients in Phase 1b trials evaluating THN391 in AD and DME.
Tara Nickerson, Ph.D., Chief Executive Officer of Therini Bio and an industry veteran who also played an instrumental role previously in several prominent private and public biotech financings, including as Chief Business Officer of Maze Therapeutics and Prothena Biosciences, remarked, 'We are deeply grateful to partner with such a distinguished investor group, both new and old. Their support enables us to significantly advance our shared vision of delivering patients a rational, innovative approach to potentially treat their debilitating conditions, including Alzheimer's disease and Diabetic Macular Edema. We look forward to advancing the Phase 1b trials to demonstrate the potential benefit of this novel mechanism in patients.'
Thomas Thestrup, Senior Principal at Angelini Ventures, who led the investment on behalf of Angelini Ventures stated, 'We are proud to support Therini Bio's mission to address the underlying vascular and inflammatory drivers of neurodegenerative disease through a truly novel approach. As an active CNS investor, we are excited about Therini's first-in-class selective antibody therapy targeting fibrin-mediated inflammation, offering a groundbreaking path to transform the treatment of diseases such as Alzheimer's and DME.'
About
Therini Bio is a clinical-stage biotech company developing immunotherapies for neuroinflammation in diseases driven by vascular dysfunction. Therini Bio is developing a pipeline of potential first-in-class therapies selectively targeting toxic fibrin accumulation for diseases, including Alzheimer's disease and Diabetic Macular Edema, where destructive neuroinflammation plays a central role in the disease process. Therini Bio's top-tier syndicate of life sciences investors includes the Alzheimer's Drug Discovery Foundation, Angelini Ventures, Apollo Health Ventures, SV Health Investors' Biotech Fund and Dementia Discovery Fund, Dolby Family Ventures, Dreavent Biotech Investments, Eli Lilly and Company, Foundation for a Better World, MRL Ventures Fund, the therapeutics-focused corporate venture fund of Merck & Co., Inc., and Sanofi Ventures. For more information, visit www.therinibio.com.
Contact
Tara Nickerson, Ph.D.Chief Executive Officertnickerson@therinibio.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
New research uncovers surprising connection between air pollution and major illness: 'The findings here showed a positive association'
New research uncovers surprising connection between air pollution and major illness: 'The findings here showed a positive association' The air quality and physical health benefits of decreasing pollution have been known for decades. But scientists are now finding even more positive effects from declining pollution rates, specifically as it pertains to one major issue— dementia. A recent international study published in Scientific Reports investigated whether greenness influences the association between particulate matter (PM) with a diameter of less than 2.5 micrometers (PM2.5) and ozone, and whether this relationship affects the disease tree that includes Alzheimer's and additional forms of dementia. Spoiler alert: the results were very positive. "The findings here showed a positive association between annual average concentrations of PM2.5 and ozone exposure and the incidence, deaths, and DALYs of AD and other dementias," read the conclusion of the study's write-up, published on "A greener environment could mitigate this association, particularly at moderate-to-high greenness levels. Therefore, increasing green space worldwide would positively impact health, although the protective effects of greenness may not increase linearly at the highest levels of vegetation." Pollution negatively impacting things like air quality and human respiratory health is kind of self-evident and wasn't ever surprising. But finding conclusive evidence of its effect on long-term neurodegenerative diseases is noteworthy and may potentially even provide a window into combating that famously hard-to-understand kind of illness. The stakes of this finding couldn't be much higher. An American Lung Association analysis found that as many as one in three people in the U.S. is breathing unhealthy air, while the World Health Organization contends that nine out of 10 people globally breathe polluted air. Meanwhile, in 2021, 57 million people had dementia worldwide, over 60% of whom live in low-and middle-income countries, and nearly 10 million new cases are diagnosed every year, per the WHO. The United States government is arguably regressing in its efforts to combat pollution these days, but many other countries around the globe are rising to the challenge, slowly but surely reducing carbon pollution in the last few decades. The effects of such reductions will likely not be readily apparent for a long time, given that industrialization has coated the atmosphere in poisonous chemicals for over a century at this point. But any progress is good progress, and the bigger (and quicker) a dent the world makes in cutting pollution, the more lives can be saved. Do you worry about the quality of the air inside your home? Yes — often Yes — but only sometimes Only when it's bad outside No — I never do Click your choice to see results and speak your mind. Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet. Solve the daily Crossword
Yahoo
14 hours ago
- Yahoo
Selonterra announces grant of United States patent on original discoveries in Alzheimer's disease
SAN MATEO, Calif., Aug. 19, 2025 /PRNewswire/ -- Selonterra, Inc. ( a biotechnology company developing transformative therapies for neurodegenerative disorders announces that the U.S. Patent and Trademark Office (USPTO) has granted the U.S. Patent No. 12,385,093 entitled "Use of APOE4 motif-mediated genes for diagnosis and treatment of Alzheimer's disease". Selonterra focuses on neurodegenerative disorders with strong genetic links, including Alzheimer's disease (AD). APOE4 is the most important genetic factor associated with late onset AD. We discovered that the single nucleotide change in APOE4 regulates the expression of genes in its chromosomal vicinity. These APOE4-motif mediated genes offer novel unexploited targets for the development of small molecule therapeutics for AD. "We relentlessly pursue intellectual property coverage along the entire development path from our early discoveries, through novel targets to small molecule composition of matter patents," said Roman Urfer, PhD, Founder and CEO of Selonterra. "The issuance of our patent around our newly discovered function of the APOE4 single nucleotide polymorphism is testament to our innovative strength," said Anne Urfer-Buchwalder, PhD, Founder and President of Selonterra. "These discoveries enable us to exploit the well-established APOE4 root cause of AD from a previously unappreciated angle." About Selonterra, Inc. Selonterra, Inc. ( pursues transformative approaches to the development of therapies of neurodegenerative disorders, Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. We harness human genetics, molecular pathway analysis and gene regulatory networks to identify proprietary disease-causing mechanisms and molecular targets, and exploit these to discover effective therapeutics. Selonterra's founders and advisors are scientists and executives with decades of biotech and pharma experience complemented by a global network of collaborator companies. Investor and Media Contact: T: (+1) 650 206 7025E: admin@ View original content to download multimedia: SOURCE Selonterra, Inc. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
14 hours ago
- Yahoo
Breakthrough study finds deficiency of this common nutrient could contribute to Alzheimer's
A deficiency of the metal lithium in the body could be a key factor contributing to the development of dementia in Alzherimer's patients, a groundbreaking new study reveals. The decade-long research, published in the journal Nature, shows for the first time that lithium occurs naturally in the brain and maintains the normal function of all its major cell types, preventing nerves from degradation. Scientists from Harvard Medical School found that lithium loss in the human brain is one of the earliest changes leading to Alzheimer's, while in mice, a similar lithium depletion accelerated memory decline. A reduced lithium level was found in some cases due to the metal's impaired uptake and its binding to amyloid plaques, which are known to be smoking gun signs of Alzheimer's. Researchers also showed that a new type of lithium compound – lithium orotate – can avoid capture by amyloid plaques and restore memory in mice. In the study, scientists used an advanced type of mass spectroscopy chemical analysis method to measure trace levels of about 30 different metals in the brain and blood samples from a range of people, including cognitively healthy people, those in an early stage of dementia, and those with advanced Alzheimer's. The analysis revealed that lithium was the only metal with markedly different levels across groups, which also seemed to change at the earliest stages of memory loss. 'Lithium turns out to be like other nutrients we get from the environment, such as iron and vitamin C,' study senior author Bruce Yankner said. 'It's the first time anyone's shown that lithium exists at a natural level that's biologically meaningful without giving it as a drug,' Dr Yankner said. Although lithium compounds have been historically in use to treat a range of mental conditions like bipolar disorder and major depressive disorder, in these cases, they are given at much higher concentrations that could even be toxic to older people. Scientists have now found that lithium orotate is effective at one-thousandth this dose – enough to mimic the natural level of lithium in the brain. The latest findings with lithium orotate, however, needs to be confirmed in humans via clinical trials. Yet, researchers suspect that measuring lithium levels could help screen people for early Alzheimer's. The findings revise the theory of Alzheimer's disease, which affects nearly 400 million people worldwide, offering a new strategy for early diagnosis, prevention, and treatment. Decades of studies have shown that Alzheimer's disease involves an array of brain abnormalities, including clumps of the protein amyloid beta, tangles of the protein tau, and a loss of the brain's protective protein REST. However, these abnormalities have never fully explained the condition. For instance, it remains unclear why some people with Alzheimer's-like changes in the brain never go on to develop dementia or cognitive decline. Recent treatments developed to target amyloid beta plaques also don't seem to reverse memory loss, only modestly reducing the rate of cognitive decline. Now, scientists say lithium could be the critical missing link. 'The idea that lithium deficiency could be a cause of Alzheimer's disease is new and suggests a different therapeutic approach,' Dr Yankner said. 'You have to be careful about extrapolating from mouse models, and you never know until you try it in a controlled human clinical trial... But so far the results are very encouraging,' he added.
